Abstract PR07: AZD9291 activity in patients with leptomeningeal disease from non-small cell lung cancer: a Phase I study
Abstract
Abstract This abstract has been withheld from publication due to its inclusion in the AACR-NCI-EORTC Molecular Targets Conference 2015 Official Press Program. It will be posted online at the time of its presentation in a press conference or in a session. Citation Format: Dae Ho Lee, Dong-Wan Kim, Myung-Ju Ahn, Byoung Chul Cho, Jong Seok Lee, Xin Ye, Pamela Yang, Haiyi Jiang, James Chih-Hsin Yang. AZD9291 activity in patients with leptomeningeal disease from non-small cell lung cancer: a Phase I study. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr PR07.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Newer-generation EGFR TKIs, including osimertinib and AZD3759, have been reported to show activity against leptomeningeal disease.
“More recently, newer-generation EGFR TKIs have been reported to show activity against leptomeningeal disease (e.g., osimertinib 122 and the CNS-penetrant EGFR TKI AZD3759).73”
Cited by
Sorted by citations
Osimertinib: First Global Approval
Greig, S. L. (2016) · Drugs · doi:10.1007/s40265-015-0533-4 · Cited by 334 · see citing works
Tan, D. S. W., Yom, S. S., Tsao, M. S., Pass, H. I., Kelly, K., Peled, N., Yung, R. C., Wistuba, I. I., Yatabe, Y., Unger, M., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.05.008 · Cited by 201 · see citing works
Piotrowska, Z., & Sequist, L. V. D. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0333 · Cited by 39 · see citing works
Erlotinib for the treatment of brain metastases in non-small cell lung cancer
Brower, J. V., & Robins, H. I. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1165206 · Cited by 37 · see citing works
Novel Treatment Strategies for Brain Metastases in Non-small-cell Lung Cancer
Bui, N. Q., Woodward, B. D., Johnson, A., & Husain, H. (2016) · Current Treatment Options in Oncology · doi:10.1007/s11864-016-0400-x · Cited by 21 · see citing works
Marked Differences in CNS Activity among EGFR Inhibitors: Case Report and Mini-Review
Pareek, V., Welch, M. R., Ravera, E., Zampolin, R. L., Sequist, L. V. D., & Halmos, B. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.07.010 · Cited by 18 · see citing works
Reungwetwattana, T., & Ou, S. I. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.01.005 · Cited by 1 · see citing works
- Authors
- Lee, D. H., Kim, D.-W., Ahn, M.-J., Cho, B. C., Lee, J. S., Ye, X., Yang, P., Jiang, H., & Yang, J. C.-H.
- Affiliations
- 1Asan Medical Center, Seoul, Korea, Republic of;
- Seoul National University Hospital (KR)
- Samsung Medical Center (KR)
- Yonsei University (KR)
- Seoul National University Bundang Hospital (KR)
- 6AstraZeneca, Shanghai, China;
- National Taiwan University Hospital (TW)
- ORCID
- Venue
- Molecular Cancer Therapeutics
- Published
- 2015-12-01
- Volume
- 14
- Issue
- 12_Supplement_2
- Pages
- PR07-PR07
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2308750957
- Cited by
- 7
- References
- 0
- Citations by year
- 2016: 7
- Type
- conference abstract
- Language
- en
- Open access
- closed
- Locations
- Molecular Cancer Therapeutics (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Brain Metastases and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- osimertinib, leptomeningeal metastasis, non-small cell lung cancer, EGFR tyrosine kinase inhibitors, brain metastases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
